Navigation Links
Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced positive results from a recently-completed multi-dose pharmacokinetic study of vaginally-administered lidocaine, which the Company is developing to prevent and treat dysmenorrhea.

This 42-subject study was designed to provide data on blood levels associated with the Company's bioadhesive vaginal lidocaine formulation at three dose strengths over multiple doses. The cohort was randomly divided into three groups, which corresponded to the three different dose strengths of the lidocaine product candidate.

"For each of the dose levels studied, use of our bioadhesive vaginal lidocaine formulation over four consecutive days was associated with blood levels that are well within an accepted range," stated George Creasy, M.D., FACOG, Columbia's vice president of clinical research and development. "At the highest dose, those blood levels are what we anticipated based on extrapolation of data from the prior, single-administration pharmacokinetic study. This indicates a positive safety profile for our lidocaine product candidate relative to the known systemic effects of lidocaine."

"This positive data strengthens our resolve to speed the path to market for our lidocaine product. We received approval from the Institutional Review Board to conduct a Phase II cross-over study with this drug candidate and we will begin recruiting patients in this study very soon," stated Robert S. Mills, president and chief executive officer of Columbia Laboratories. "There are approximately 5.6 million women who suffer from the painful menstrual cramping that characterizes dysmenorrhea, which limits their normal activities and causes them to lose time from school or work. We believe our lidocaine product can fill a real unmet medical need and improve the lives of these women, assuming positive data in current and future c
'"/>




Page: 1 2 3

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... , March 4, 2015 Aethlon Medical, Inc. (OTCQB:AEMD), ... infectious diseases and cancer, today announced that James ... present a corporate overview at the 27th Annual ROTH ... in Laguna Niguel, California . To ... http://www.roth.com/main/page.aspx?PageID=7207 ). A live webcast of the ...
(Date:3/4/2015)... 4, 2015  Heska Corporation (Nasdaq: HSKA ... to Join Its Fourth Quarter and Year End 2014 ... @ 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: www.heska.com ... Earnings Call link on the front page of this ... the web at the address above.  Alternatively, you may ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2Aethlon Medical to Present at the 27th Annual ROTH Conference 2Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... Feb. 1, 2011 A breakthrough in stroke research ... stroke survivors has published today. In the February 1, ... the first human results of a new method of ... Rapid improvement in impaired motor function, gait, hand function, ...
... SHENZHEN, China, Feb. 1, 2011 /PRNewswire-Asia/ -- ... rapidly growing international trading company in China, ... possible prospective business partners today, as the ... moving towards the final signing of future ...
Cached Medicine Technology:Inflammation Identified as New Therapeutic Target Years After Stroke 2Ongoing Negotiation on Top Brand Health Device Cooperation 2
(Date:3/4/2015)... Jeannie Mai, TV personality, fashion maven, and co-host ... of the print publication. Mai embraces the overall theme of ... for clothes and personal care products. In an exclusive interview, ... to an organic diet. She mentions, “Having an organic lifestyle ... but also now as I’m a full time student at ...
(Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
(Date:3/4/2015)... March 04, 2015 Problem Gambling Awareness ... to join individuals and organizations across the nation in ... public, health care professionals, policymakers, and others about problem ... on Compulsive Gambling (FCCG) and FCCG partner organizations are ... screen patients for a gambling problem, to make treatment ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 A new ... showing promise in terms of extending life. Studies ... that this new dieting routine can help extend life ... production clearly has long term benefits, many suffering from ... a quicker substitute is necessary. As an alternative to ...
(Date:3/4/2015)... 04, 2015 Dietary supplement company ... world’s first biocompatible copper chelate, at Natural Products Expo ... the chance to gain insight into their wellness through ... Cunermuspir complex can support their individual nutritional needs, all ... is the core ingredient of the MitoSynergy product line, ...
Breaking Medicine News(10 mins):Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Problem Gambling - A Public Health Issue; March Is Problem Gambling Awareness Month 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3Health News:MitoSynergy Invites Expo West Attendees to Sit Back, Relax and Take Time for Their Health 2
... scientists have said that degradation of the eco systems// of ... and may cause greater harm in next 50 years. ... a major outbreak and new diseases are emerging because of ... being used in unsustainable way. ,The report emphasizes that ...
... drug raloxifene, used for treating osteoporosis is also able to ... are in their postmenopausal age. ,The study observed women ... mg of raloxifene daily for bone fractures due to osteoporosis ... After three years, all women were tested for cognitive impairments ...
... completed the second phase of testing of the vaccine ... cervical cancers and 90% of genital warts. ,277 ... 36 months and regularly had gynecological examination, cervicovaginal sampling ... antibodies to HPV. , ,The results showed the ...
... onions may be the key to avoid the risk of ... in onions, a peptide called GPCS that seems to prevent ... cells of newborn mice that were treated with parathyroid hormone ... exposed to the peptide GPCS. The treatment with the peptide ...
... In a study trying to find out the relationship between ... 585 confirmed cases of pancreatic cancer and 4779 healthy people ... pancreas is pancreatic cancer and it spreads through the lymphatic ... smoking etc had been known to increase the risk of ...
... the risk of diabetes. Obese people may be a t ... A study by UT Southwestern Medical Center of US suggests ... have a genetic component. ,The study had evaluated ... type II in people. The study was conducted on 679 ...
Cached Medicine News:
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size....
Medicine Products: